Molecular-targeted agents for enhancing tumour response

2009 ◽  
pp. 287-300 ◽  
Author(s):  
Michael Baumann ◽  
Vincent Grégoire
Keyword(s):  
Tumour Response ◽  
Targeted Agents ◽  
Molecular Targeted Agents

Molecular targeted agents for enhancing tumour response

2018 ◽  
pp. 230-240
Author(s):  
Michael Baumann ◽  
Mechthild Krause ◽  
Vincent Grégoire
Keyword(s):  
Tumour Response ◽  
Targeted Agents ◽  
Molecular Targeted Agents

scholarly journals MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

2019 ◽  
Vol 10 (10) ◽  
Author(s):  
Bin Yang ◽  
Chunping Wang ◽  
Hui Xie ◽  
Yiwu Wang ◽  
Jiagan Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Notch Signaling ◽  
Signaling Pathway ◽  
Epithelial Mesenchymal Transition ◽  
Notch Signaling Pathway ◽  
Advanced Hepatocellular Carcinoma ◽  
Targeted Agents ◽  
Mesenchymal Transition ◽  
Molecular Targeted Agents ◽  
Hcc Cells

Abstract Molecular targeted agents, such as sorafenib, remain the only choice of an antitumor drug for the treatment of advanced hepatocellular carcinoma (HCC). The Notch signaling pathway plays central roles in regulating the cellular injury/stress response, anti-apoptosis, or epithelial–mesenchymal transition process in HCC cells, and is a promising target for enhancing the sensitivity of HCC cells to antitumor agents. The ADAM metalloprotease domain-17 (ADAM-17) mediates the cleavage and activation of Notch protein. In the present study, microRNA-3163 (miR-3163), which binds to the 3′-untranslated region of ADAM-17, was screened using online methods. miRDB and pre-miR-3163 sequences were prepared into lentivirus particles to infect HCC cells. miR-3163 targeted ADAM-17 and inhibited the activation of the Notch signaling pathway. Infection of HCC cells with miR-3163 enhanced their sensitivity to molecular targeted agents, such as sorafenib. Therefore, miR-3163 may contribute to the development of more effective strategies for the treatment of advanced HCC.

scholarly journals Management of metastatic renal cell carcinoma – mini review

2015 ◽  
Vol 2 (2) ◽  
pp. 75-83 ◽  
Author(s):  
Anubha Bharthuar ◽  
Himanshu Pandey ◽  
Swapan Sood
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Novel Agents ◽  
Targeted Agents ◽  
Clinical Variability ◽  
Biological Heterogeneity ◽  
Molecular Targeted Agents

The management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the last decade. A number of different systemic molecular targeted agents that have been recently approved have improved the survival of patients with mRCC. This mini-review focuses on the implementation of multi-modality therapy in the management of mRCC and the approved indications of the various available novel agents. These novel agents have expanded our armamentarium and improved clinical outcomes of this challenging disease that has considerable biological heterogeneity and clinical variability.  

Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents

2006 ◽  
Vol 18 (3) ◽  
pp. 247-252 ◽  
Author(s):  
Francesco Caponigro ◽  
Amalia Milano ◽  
Maria Basile ◽  
Franco Ionna ◽  
Rosario Vincenzo Iaffaioli
Keyword(s):  
Head And Neck Cancer ◽  
Cancer Therapy ◽  
Head And Neck ◽  
Neck Cancer ◽  
Targeted Agents ◽  
Recent Advances ◽  
Molecular Targeted Agents
Sign in / Sign up

Export Citation Format

Share Document